Public Health Priorities in 2024 State Legislatures Webinar
Wednesday, February 28, 12:30pm PT / 3:30 pm ET
Hosted by the American Public Health Association & Act for Public Health
Join this one-hour webinar to discuss public health priorities for the state legislative sessions. Hear from the Association of State and Territorial Health Officials, the Local Solutions Support Center, and the Massachusetts Public Health Association about legislative trends that affect public health. We hope that this webinar will equip you to accomplish more informed advocacy in the 2024 legislative session and beyond.
Advancing Racial & Health Justice Through a Right to Counsel for Tenants
Wednesday, March 6, 11am PT / 2:00pm ET
Hosted by Human Impact Partners, National Coalition for a Civil Right to Counsel, Results for America, ChangeLab Solutions & PolicyLink
ChangeLab Solutions attorney Melissa Marichal Zayas will join experts who are working to pass, implement, and evaluate right-to-counsel efforts. Tune in to learn more about right-to-counsel laws and steps that public health practitioners can take to advance racial and health justice by supporting the right to counsel for tenants facing eviction. Webinar attendees will be the first to preview and receive the new resource Advancing Racial & Health Justice Through a Right to Counsel for Tenants: A Primer for the Public Health Field.
APAICS Health Summit 2024
Thursday, March 21, 9:00am PT / 12:00pm ET
Hosted by the Asian Pacific American Institute for Congressional Studies
Iyanrick John, vice president of external affairs at ChangeLab Solutions, will be hosting a panel discussion, Closing Gaps: Advancing DEI in Health Research, as part of the Asian Pacific American Institute for Congressional Studies (APAICS) Health Summit. Major hurdles to engaging Asian Americans, Native Hawaiians, and Pacific Islanders in clinical research include mistrust, lack of information, and poor representation across the diaspora. This panel will explore the multifaceted challenges of health research, including diversity within clinical trials, disaggregated data of trial results, and the need for additional investment in studying rare diseases that disproportionately affect Asian Americans, Native Hawaiians, and Pacific Islanders.